ORLANDO, Fla.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) today reported that clinical investigators from leading cancer research centers presented data from recent and ongoing clinical trials of both PROSTASCINT® (capromab pendetide) and QUADRAMET® (samarium Sm-153 lexidronam injection) in prostate cancer at the 2007 Prostate Cancer Symposium, multidisciplinary meeting co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Therapeutic Radiology and Oncology (ASTRO), and the Society of Urologic Oncology (SUO) held February 22-24, 2007 in Orlando, Florida. The six PROSTASCINT-related presentations were highlighted by two studies that evaluated the outcomes of prostate cancer patients based on the image findings of PROSTASCINT. The two QUADRAMET-related presentations were focused on the safety and efficacy of QUADRAMET in combination with taxane-based chemotherapy for prostate cancer patients.
